# A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

> **NCT02812394** · PHASE1 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** CVT-301 (Dose Level 1)
- **DRUG:** CVT-301 (Dose Level 2)
- **DRUG:** Sinemet®

## Key facts

- **NCT ID:** NCT02812394
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2016-08
- **Final completion:** 2016-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02812394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02812394, "A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02812394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*